# US 2014/0294828 A1 · Alphabodies specifically binding to viral proteins and methods for producing the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0294828 A1
- Document ID: US20140294828A1
- Status: Published application
- Kind: A1
- Application number: 13/994,106
- Filed: 2011-01-06
- Published: 2014-10-02
- Earliest claimed: 2011-01-06
- Assignees: Complix NV
- Inventors: Johan Desmet; Ignace Lasters; Geert Meersseman; Sabrina Deroo
- Web page: https://patentgrep.com/patent/US20140294828A1

## CPC

- C07K 16/08: against material from viruses
- C07K 16/1145: {Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site}
- G01N 33/56988: {HIV or HTLV}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2318/20: Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides methods for the production of single-chain Alphabody polypeptides having detectable binding affinity for, or detectable in vitro activity on, a viral protein of interest, which comprising the step of producing a single-chain Alphabody library comprising at least 100 different-sequence single-chain Alphabody polypeptides, wherein said Alphabody polypeptides differ from each other in at least one of a defined set of 5 to 20 variegated amino acid residue positions, and wherein said variegated amino acid residue positions are located at specific positions in one or more of the alpha-helices of the Alphabody or the linker fragment connecting two consecutive alpha-helices of the Alphabody polypeptides. The invention further provides Alphabodies obtainable by the methods of the invention and uses thereof.

## Claims

### Claim 1

A method for the production of at least one single-chain Alphabody polypeptide having detectable binding affinity for, or detectable in vitro activity on, a viral protein of interest, said method at least comprising the steps of:
a) producing a single-chain Alphabody library comprising at least 100 different-sequence single-chain Alphabody polypeptides, wherein said Alphabody polypeptides differ from each other in at least one of a defined set of 5 to 20 variegated amino acid residue positions, and wherein at least 70% of said variegated amino acid residue positions are located either:
(i) at heptad e-positions in a first alpha-helix of the Alphabody polypeptides and at heptad g-positions in a second alpha-helix, and optionally at heptad b-positions in said first alpha-helix of the Alphabody polypeptides and/or at heptad c-positions in said second alpha-helix of the Alphabody polypeptides, or
(ii) at heptad b-, c- and f-positions in one alpha-helix of the Alphabody polypeptides, or
(iii) at positions in a linker fragment connecting two consecutive alpha-helices of the Alphabody polypeptides, and
b) selecting from said single-chain Alphabody library at least one single-chain Alphabody having detectable binding affinity for, or detectable in vitro activity on, said viral protein of interest.

### Claim 2 (depends on 1)

The method according to claim 1, wherein step a) of producing a single-chain Alphabody library comprises the steps of:
a1) producing a nucleic acid or vector library encoding a single-chain Alphabody library comprising at least 100 different-sequence single-chain Alphabody polypeptides, wherein said Alphabody polypeptides differ from each other in at least one of a defined set of 5 to 20 variegated amino acid residue positions, and wherein at least 70% of said variegated amino acid residue positions are located either:
(i) at heptad e-positions in a first alpha-helix of the Alphabody polypeptides and at heptad g-positions in a second alpha-helix, and optionally at heptad b-positions in said first alpha-helix of the Alphabody polypeptides and/or at heptad c-positions in said second alpha-helix of the Alphabody polypeptides, or
(ii) at heptad b-, c- and f-positions in one alpha-helix of the Alphabody polypeptides, or
(iii) at positions in a linker fragment connecting two consecutive alpha-helices of the Alphabody polypeptides, and
a2) expressing said nucleic acid or vector library under conditions suitable for the production of said single-chain Alphabody library.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the step a2) of expressing said nucleic acid or vector library, comprises introducing said nucleic acid or vector library into host cells and culturing said host cells in a medium under conditions suitable for the production of said single-chain Alphabody library.

### Claim 4 (depends on 2)

The method according to claim 2, further comprising the step of isolating the single-chain Alphabody library produced in step a2) from said host cells and/or from said medium.

### Claim 5 (depends on 1)

The method according to claim 1, wherein step b) of selecting from said single-chain Alphabody library at least one single-chain Alphabody having detectable binding affinity for, or detectable in vitro activity on, said viral protein of interest, comprises contacting said viral protein of interest with the single-chain Alphabody library produced in step a).

### Claim 6 (depends on 1)

The method according to claim 1, further comprising the step of isolating from said single-chain Alphabody library at least one single-chain Alphabody having detectable binding affinity for, or detectable in vitro activity on, said viral protein of interest.

### Claim 7 (depends on 1)

The method according to claim 1, wherein said Alphabody library is enriched for single-chain Alphabodies having detectable binding affinity for, or detectable in vitro activity on, said viral protein of interest.

### Claim 8 (depends on 7)

The method according to claim 7, wherein said Alphabody library is enriched for single-chain Alphabodies having detectable binding affinity for, or detectable in vitro activity on, said viral protein of interest by iterative execution of step b) of selecting from said single-chain Alphabody library at least one single-chain Alphabody having detectable binding affinity for, or detectable in vitro activity on, said viral protein of interest.

### Claim 9 (depends on 1)

The method according to claim 1, further comprising the step of amplifying said at least one single-chain Alphabody having detectable binding affinity for, or detectable in vitro activity on, said viral protein of interest.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the viral protein is a viral fusion protein.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the viral protein is selected from the group consisting of the gp120 protein of HIV-1 virus, the HA1 and HA2 proteins of influenza, the F protein of respiratory syncytial virus, the HA protein of Influenza A virus, the HEF protein of influenza C virus, the F protein of Simian parainfluenza virus, the F protein of Human parainfluenza virus, the F protein of Newcastle disease virus, the F2 protein of measles, the F2 protein of Sendai virus, the gp2 protein of Ebola virus, the TM protein of Moloney murine leukemia virus, the gp41 protein of HIV-1, the gp41 protein of Simian immunodeficiency virus, the gp21 protein of Human T-cell leukemia virus 1, the TM protein of Human syncytin-2, the TM protein of Visna virus, the S2 protein of Mouse hepatitis virus, the E2 protein of SARS corona virus, the E protein of Tick-borne encephalitis virus, the E2 protein of Dengue 2 and 3 virus, the E protein of Yellow Fever virus, the E protein of West Nile virus, the E1 protein of Semliki forest virus, the E1 protein of Sindbis virus, the G protein of Rabies virus, the G protein of Vesicular stomatitis virus, and the gB protein of Herpes simplex virus.

### Claim 12 (depends on 1)

A single-chain Alphabody polypeptide having detectable binding affinity for, or detectable in vitro activity on, a viral protein of interest obtainable by the method according to claim 1.

### Claim 13 (depends on 12)

A nucleic acid encoding a single-chain Alphabody polypeptide according to claim 12.

### Claim 14 (depends on 13)

A vector comprising a nucleic acid according to claim 13.

### Claim 15 (depends on 13)

A host cell comprising a nucleic acid according to claim 13.

### Claim 16 (depends on 12)

Pharmaceutical composition comprising a single-chain Alphabody polypeptide according to claim 12.

### Claim 17 (depends on 12)

A method of treatment for a patient suffering from a viral disease or a viral infection, comprising the administration of an effective amount of the single-chain Alphabody polypeptide according to claim 12.

### Claim 18

(canceled)

### Claim 19 (depends on 14)

A host cell comprising a vector according to claim 14.
